Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres

BACKGROUND: Nintedanib has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). It was approved by the National Institute for Health and Care Excellence (NICE) in January 2016 for IPF patients with a forced vital capacity (FVC) of 50–80% in the United Kingdom...

Descripción completa

Detalles Bibliográficos
Autores principales: Toellner, Hannah, Hughes, G., Beswick, W., Crooks, M. G., Donaldson, C., Forrest, I., Hart, S. P., Leonard, C., Major, M., Simpson, A. J., Chaudhuri, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670096/
https://www.ncbi.nlm.nih.gov/pubmed/29101500
http://dx.doi.org/10.1186/s40169-017-0172-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670096/
https://www.ncbi.nlm.nih.gov/pubmed/29101500
http://dx.doi.org/10.1186/s40169-017-0172-3

Ejemplares similares